$58.08
0.570.99%
At Close: -
$58.08
00.00%
After Hours: Jul 26, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Twist Bioscience (NASDAQ:TWST) Stock, Analyst Ratings, Price Targets, Forecasts
Twist Bioscience Corp has a consensus price target of $46.1 based on the ratings of 10 analysts. The high is $65 issued by TD Cowen on June 13, 2024. The low is $27 issued by Berenberg on September 27, 2023. The 3 most-recent analyst ratings were released by Goldman Sachs, Barclays, and TD Cowen on July 9, 2024, June 28, 2024, and June 13, 2024, respectively. With an average price target of $60 between Goldman Sachs, Barclays, and TD Cowen, there's an implied 3.31% upside for Twist Bioscience Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Barclays
TD Cowen
Guggenheim
Scotiabank
1calculated from analyst ratings
Analyst Ratings for Twist Bioscience
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/09/2024 | Buy Now | -5.3% | Goldman Sachs | Matthew Sykes | $45 → $55 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 3.31% | Barclays | Luke Sergott | $45 → $60 | Maintains | Overweight | Get Alert |
| 06/13/2024 | Buy Now | 11.91% | TD Cowen | Steven Mah | $55 → $65 | Maintains | Buy | Get Alert |
| 06/05/2024 | Buy Now | -8.75% | Guggenheim | Subbu Nambi | → $53 | Initiates | → Buy | Get Alert |
| 05/06/2024 | Buy Now | -17.36% | Scotiabank | Sung Ji Nam | $43 → $48 | Maintains | Sector Outperform | Get Alert |
| 05/03/2024 | Buy Now | -13.91% | Evercore ISI Group | Vijay Kumar | $46 → $50 | Maintains | Outperform | Get Alert |
| 05/03/2024 | Buy Now | -22.52% | Barclays | Luke Sergott | $40 → $45 | Maintains | Overweight | Get Alert |
| 05/03/2024 | Buy Now | -31.13% | Baird | Catherine Ramsey | $39 → $40 | Maintains | Outperform | Get Alert |
| 04/10/2024 | Buy Now | -31.13% | Barclays | Luke Sergott | $45 → $40 | Maintains | Overweight | Get Alert |
| 02/05/2024 | Buy Now | -25.96% | Scotiabank | Sung Ji Nam | $30 → $43 | Maintains | Sector Outperform | Get Alert |
| 01/25/2024 | Buy Now | -22.52% | Barclays | Luke Sergott | $30 → $45 | Maintains | Overweight | Get Alert |
| 01/18/2024 | Buy Now | -22.52% | Goldman Sachs | Matthew Sykes | $25 → $45 | Maintains | Buy | Get Alert |
| 01/17/2024 | Buy Now | -22.52% | Goldman Sachs | Matthew Sykes | $25 → $45 | Upgrade | Neutral → Buy | Get Alert |
| 09/27/2023 | Buy Now | -53.51% | Berenberg | Gaurav Goparaju | → $27 | Initiates | → Buy | Get Alert |
| 08/07/2023 | Buy Now | -55.23% | Barclays | Luke Sergott | $20 → $26 | Maintains | Overweight | Get Alert |
| 07/13/2023 | Buy Now | -65.56% | Goldman Sachs | Matthew Sykes | $18 → $20 | Maintains | Neutral | Get Alert |
| 05/08/2023 | Buy Now | -69.01% | Baird | Catherine Ramsey | $29 → $18 | Maintains | Outperform | Get Alert |
| 05/08/2023 | Buy Now | -65.56% | Barclays | Luke Sergott | $32 → $20 | Maintains | Overweight | Get Alert |
| 04/19/2023 | Buy Now | -65.56% | Goldman Sachs | Matthew Sykes | $43 → $20 | Maintains | Neutral | Get Alert |
| 04/18/2023 | Buy Now | -65.56% | Goldman Sachs | Matthew Sykes | $43 → $20 | Maintains | Neutral | Get Alert |
| 02/06/2023 | Buy Now | -25.96% | Goldman Sachs | Matthew Sykes | $50 → $43 | Maintains | Neutral | Get Alert |
| 02/06/2023 | Buy Now | -50.07% | Baird | Catherine Ramsey | $33 → $29 | Maintains | Outperform | Get Alert |
| 02/06/2023 | Buy Now | -44.9% | Barclays | Luke Sergott | $37 → $32 | Maintains | Overweight | Get Alert |
| 01/30/2023 | Buy Now | -36.29% | Barclays | Luke Sergott | $43 → $37 | Maintains | Overweight | Get Alert |
| 01/05/2023 | Buy Now | -43.18% | Scotiabank | Sung Ji Nam | → $33 | Initiates | → Sector Outperform | Get Alert |
| 01/03/2023 | Buy Now | -38.02% | Evercore ISI Group | Vijay Kumar | $28 → $36 | Upgrade | In-Line → Outperform | Get Alert |
| 11/21/2022 | Buy Now | -43.18% | Baird | Catherine Schulte | $56 → $33 | Maintains | Outperform | Get Alert |
| 11/21/2022 | Buy Now | -25.96% | Barclays | Luke Sergott | $45 → $43 | Maintains | Overweight | Get Alert |
| 11/21/2022 | Buy Now | -48.35% | SVB Leerink | Puneet Souda | $45 → $30 | Maintains | Market Perform | Get Alert |
| 10/07/2022 | Buy Now | -22.52% | SVB Leerink | Puneet Souda | $50 → $45 | Maintains | Market Perform | Get Alert |
| 10/06/2022 | Buy Now | -22.52% | Barclays | Luke Sergott | $55 → $45 | Maintains | Overweight | Get Alert |
| 08/08/2022 | Buy Now | -5.3% | Barclays | Luke Sergott | $45 → $55 | Maintains | Overweight | Get Alert |
| 08/08/2022 | Buy Now | -13.91% | SVB Leerink | Puneet Souda | $45 → $50 | Maintains | Market Perform | Get Alert |
| 07/13/2022 | Buy Now | -22.52% | Barclays | Luke Sergott | $40 → $45 | Maintains | Overweight | Get Alert |
| 05/09/2022 | Buy Now | -31.13% | Barclays | Luke Sergott | $60 → $40 | Maintains | Overweight | Get Alert |
| 04/13/2022 | Buy Now | -5.3% | Goldman Sachs | Matthew Sykes | $105 → $55 | Maintains | Neutral | Get Alert |
| 02/07/2022 | Buy Now | 29.13% | Barclays | Luke Sergott | $130 → $75 | Maintains | Overweight | Get Alert |
| 02/07/2022 | Buy Now | 20.52% | SVB Leerink | Puneet Souda | $110 → $70 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Twist Bioscience (TWST) stock?
The latest price target for Twist Bioscience (NASDAQ:TWST) was reported by Goldman Sachs on July 9, 2024. The analyst firm set a price target for $55.00 expecting TWST to fall to within 12 months (a possible -5.30% downside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Twist Bioscience (TWST)?
The latest analyst rating for Twist Bioscience (NASDAQ:TWST) was provided by Goldman Sachs, and Twist Bioscience maintained their buy rating.
When was the last upgrade for Twist Bioscience (TWST)?
The last upgrade for Twist Bioscience Corp happened on January 17, 2024 when Goldman Sachs raised their price target to $45. Goldman Sachs previously had a neutral for Twist Bioscience Corp.
When was the last downgrade for Twist Bioscience (TWST)?
There is no last downgrade for Twist Bioscience.
When is the next analyst rating going to be posted or updated for Twist Bioscience (TWST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Twist Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Twist Bioscience was filed on July 9, 2024 so you should expect the next rating to be made available sometime around July 9, 2025.
Is the Analyst Rating Twist Bioscience (TWST) correct?
While ratings are subjective and will change, the latest Twist Bioscience (TWST) rating was a maintained with a price target of $45.00 to $55.00. The current price Twist Bioscience (TWST) is trading at is $58.08, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.